Riociguat for the Treatment of Pulmonary Arterial Hypertension

Guidelines for the diagnosis and treatment of pulmonary hypertension

Galiè, N., Hoeper, M. M., Humbert, M. J. C., Torbicki, A., Vachiéry, J., Barberà, J. A., Beghetti, M., Corris, P. A., Gaine, S., Gibbs, J. S. R., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,853

Bosentan Therapy for Pulmonary Arterial Hypertension

Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., KEOGH, A. M., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,718

A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension

Barst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. Μ., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,688

Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension

Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D. B., Fleming, T. R., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,466

ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension

McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,359

Inhaled Iloprost for Severe Pulmonary Hypertension

Olschewski, H., Simonneau, G., Galiè, N., HIGENBOTTAM, T. W., Naeije, R., Rubin, L. J., Nikkho, S. M., Speich, R., Hoeper, M. M., Behr, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020204 · Cited by 1,783

Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension

Ghofrani, H. A., D’Armini, A. M., Grimminger, F., Hoeper, M. M., Jansa, P., Kim, N. H., Mayer, E., Simonneau, G., Wilkins, M. R., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209657 · Cited by 1,393

Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension: Comparison with Cardiopulmonary Exercise Testing

Miyamoto, S., Nagaya, N., Satoh, T., Kyotani, S., Sakamaki, F., Fujita, M., Nakanishi, N., & Miyatake, K. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.9906015 · Cited by 1,147

An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry

Benza, R. L., Miller, D. P., Barst, R. J., Badesch, D. B., Frost, A., & McGoon, M. D. (2012) · CHEST Journal · doi:10.1378/chest.11-1460 · Cited by 1,107

ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension

McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M., Rosenson, R. S., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192230 · Cited by 1,096

Recent developments in connective tissue disease associated pulmonary arterial hypertension

Rodolfi, S., Ong, V. H., & Denton, C. P. (2024) · International Journal of Cardiology Congenital Heart Disease · doi:10.1016/j.ijcchd.2024.100513 · Cited by 6

Systemic pharmacotherapy approaches for the treatment of systemic sclerosis

Donato, S. D., McMahan, Z. H., & Hughes, M. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2470846 · Cited by 6

Revisiting Acute Decompensated Right Ventricle Failure in Pulmonary Arterial Hypertension

Masih, R., Paudyal, V., Basnet, Y. M., Sunesara, S., Sharma, M., & Surani, S. (2025) · The Open Respiratory Medicine Journal · doi:10.2174/0118743064359315250210080743 · Cited by 6

Current and future direction in the management of scleroderma

Brady, S. M., Shapiro, L. S., & Mousa, S. A. (2016) · Archives of Dermatological Research · doi:10.1007/s00403-016-1647-6 · Cited by 6

The changing paradigm in pulmonary hypertension trials

LeVarge, B. L., & Channick, R. N. (2015) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000197 · Cited by 6

Pharmacological update: New drugs in cardiac practice: A critical appraisal

Choudhury, A., Magoon, R., Malik, V., Sharma, R., & Kapoor, P. M. (2017) · Annals of Cardiac Anaesthesia · doi:10.4103/0971-9784.197798 · Cited by 6

Update on pulmonary arterial hypertension research: proceedings from a meeting of experts

McLaughlin, V. V., Bacchetta, M. D., Badesch, D. B., Benza, R. L., Burger, C. D., Chin, K., Frantz, R. P., Frost, A., Hemnes, A. R., Kim, N. H., et al. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1404974 · Cited by 6

Critical Care of Patients With Cardiopulmonary Complications of Sarcoidosis

Lui, J. K., MESFIN, N. M., Tugal, D., Klings, E. S., Govender, P., & Berman, J. S. (2021) · Journal of Intensive Care Medicine · doi:10.1177/0885066621993041 · Cited by 6

FoxO4 controls sGCβ transcription in vascular smooth muscle

Galley, J. C., Miller, M. P., Sanker, S., Liu, M., Sharina, I. G., Martin, E., Gomez, D. A., & Straub, A. C. (2022) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00551.2021 · Cited by 6

Emerging Evidence and Treatment Perspectives from Randomized Clinical Trials in Systemic Sclerosis: Focus on Interstitial Lung Disease

Aragona, C. O., Versace, A. G., Ioppolo, C., Rosa, D. L., Lauro, R., Tringali, M. C., Tomeo, S., Ferlazzo, G., Roberts, W. N., Bitto, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10020504 · Cited by 6

Management of Pulmonary Arterial Hypertension

Weatherald, J. C., Varughese, R. A., Liu, J., & Humbert, M. J. C. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0043-1770118 · Cited by 7

Assessment and management of patients with portopulmonary hypertension undergoing liver transplantation

Paine, G. W., Toolan, M., Nayagam, J. S., Joshi, D., Hogan, B. J., McCabe, C., Marino, P. S., & Patel, S. (2023) · Journal of Liver Transplantation · doi:10.1016/j.liver.2023.100169 · Cited by 6

Current Management and Future Directions for Pulmonary Arterial Hypertension Associated with Congenital Heart Disease

Mahmoud, A., Abbas, M. T., Kamel, M., Farina, J., Pereyra, M., Scalia, I. G., Barry, T., Chao, C., Marcotte, F., Ayoub, C., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm14010005 · Cited by 6

Impact of Rapid Sequential Combination Therapy on Distinct Haemodynamic Measures in Newly Diagnosed Pulmonary Arterial Hypertension

Kramer, T., Nattmann, P., Gerhardt, F., Stafiej, P., Dumitrescu, D., ten Freyhaus, H., Wißmüller, M., Hohmann, C., Baldus, S. E., & Rosenkranz, S. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14611 · Cited by 6

Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis

Khanna, D., Kramer, F., Höfler, J., Ghadessi, M., Sandner, P., Allanore, Y., Denton, C. P., Kuwana, M., Matucci‐Cerinic, M., Pope, J. E., et al. (2024) · Rheumatology · doi:10.1093/rheumatology/keae150 · Cited by 6

Pulmonary hypertension and breathlessness: is it a combination we can ignore?

Strange, G. A., Williams, T. J., Kermeen, F. D., Whyte, K., & KEOGH, A. M. (2013) · Internal Medicine Journal · doi:10.1111/imj.12321 · Cited by 6

Progress in the understanding and management of pulmonary arterial hypertension

Chakrabarti, A. M., Mitchell, J. A., & Wort, S. J. (2015) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2015.13 · Cited by 6

Translational In Vivo Models for Cardiovascular Diseases

Fliegner, D., Gerdes, C., Meding, J., & Stasch, J. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_31 · Cited by 6

ESC-Leitlinien 2015 zur pulmonalen Hypertonie

Olschewski, H., & Kovács, G. (2015) · Herz · doi:10.1007/s00059-015-4381-5 · Cited by 6

Riociguat for the treatment of pulmonary hypertension: a safety evaluation

Binder, C., Zotter‐Tufaro, C., & Bonderman, D. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1248400 · Cited by 6

Current Trends and Future Perspectives in the Treatment of Pulmonary Arterial Hypertension

Bhogal, S. S., Mukherjee, D., Banerjee, S., Tan, W., & Paul, T. K. (2017) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2017.10.002 · Cited by 6

Epidemiology of pulmonary hypertension in colombia

Machado, P. A. M., Sáenz, R. C. G., Ivan Baños, A., & Álvaro Alvarez, B. (2019) · Salud Uninorte · doi:10.14482/sun.34.3.614.4 · Cited by 6

Strategies for the management of pulmonary arterial hypertension in patients with congenital heart disease

Liew, N., Rashid, Z., & Tulloh, R. M. R. (2020) · Journal of Congenital Cardiology · doi:10.1186/s40949-020-00052-w · Cited by 6

sGC Activity and Regulation of Blood Flow in a Zebrafish Model System

Vishnolia, K. K., Raković, A., Hoene, C., Tarhbalouti, K., Aherrahrou, Z., & Erdmann, J. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.633171 · Cited by 6

Role of pulmonary arterial capacitance in predicting mortality in patients with pulmonary hypertension: A systematic review and meta-analysis

Rajdev, K., Lahan, S., & Wichman, T. O. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.02.043 · Cited by 6

Angiotensin II augments renal vascular smooth muscle soluble GC expression via an AT1 receptor–forkhead box subclass O transcription factor signalling axis

Galley, J. C., Hahn, S. A., Miller, M. P., Durgin, B. G., Jackson, E. K., Stocker, S. D., & Straub, A. C. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15522 · Cited by 6

Cyclic GMP-Dependent Regulation of Vascular Tone and Blood Pressure Involves Cysteine-Rich LIM-Only Protein 4 (CRP4)

Längst, N., Adler, J., Schweigert, O., Kleusberg, F. M., Santos, M. C., Knauer, A., Sausbier, M., Zeller, T., Ruth, P., & Łukowski, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189925 · Cited by 6

Portopulmonary hypertension

Lv, Y., Han, G., & Fan, D. (2016) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2016.1157895 · Cited by 6

Acute Right Ventricular Failure

Cucci, A. R., Kline, J. A., & Lahm, T. (2014) · Respiratory medicine · doi:10.1007/978-1-4939-1065-6_9 · Cited by 6

Nitric oxide in paediatric respiratory disorders: novel interventions to address associated vascular phenomena?

Akter, F., Coghlan, G., & de Mel, A. (2016) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944716649893 · Cited by 6

Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension

Swisher, J. W., & Elliott, D. (2016) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2016.11.012 · Cited by 6

Evaluation of Clinical Outcomes and Simultaneous Digital Tracking of Daily Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Protocol for the Observational VENTASTEP Study

Mueller, C., Stollfuß, B., Roitenberg, A., Harder, J., & Richter, M. J. (2018) · JMIR Research Protocols · doi:10.2196/12144 · Cited by 6

Update on Medical Management of Pulmonary Arterial Hypertension

Sherman, A. E., Saggar, R., & Channick, R. N. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.08.002 · Cited by 6

Comprehensive Monitoring in Patients With Dual Lumen Right Atrium to Pulmonary Artery Right Ventricular Assist Device

Usman, A. A., Spelde, A. E., Ibrahim, M., Cevasco, M., Bermudez, C., MacKay, E. J., Khandhar, S., Szeto, W., Vernick, W., & Gutsche, J. (2022) · ASAIO Journal · doi:10.1097/mat.0000000000001684 · Cited by 6

Coronary Vasospasm

Savage, M. P., & Moe, T. G. (2021) · JACC Case Reports · doi:10.1016/j.jaccas.2021.01.022 · Cited by 6

Inflammation and Obesity Correlate in Pulmonary Hypertension but Are Associated with Diverging Outcomes

Bie, E. M. D. D. D., Correa‐Jaque, P., Jones, R. J., Bogaard, H. J., Chan, J. T. N., Church, C., Coghlan, G., Gaur, A., Ghio, S., Ghofrani, H. A., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202412-2393oc · Cited by 5

Haemodynamic responses to sotatercept and parenteral prostacyclins in pulmonary arterial hypertension patients

Genecand, L., Boucly, A., Beurnier, A., Jaïs, X., Degano, B., Prevot, G., Gerges, C., Lamblin, N., Bauer, F., Savale, L., et al. (2026) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2026.05.028 · Cited by 5

Inhaled sGC Modulator Can Lower PH in Patients With COPD Without Deteriorating Oxygenation

Saffaran, S., Wang, W., Das, A., Schmitt, W., Becker‐Pelster, E., Hardman, J. G., Weimann, G., & Bates, D. G. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12308 · Cited by 5

Regular Risk Assessment in Pulmonary Arterial Hypertension - A Whistleblower for Hidden Disease Progression.

Wu, S., & Wu, Y. (2022) · PubMed Central · doi:10.6515/acs.202203_38(2).20211005a · Cited by 5

Fetal therapies in congenital diaphragmatic hernia: a review of possibilities and practical challenges

Dekirmendjian, A., Doktor, F., Antounians, L., & Zani, A. (2025) · Seminars in Fetal and Neonatal Medicine · doi:10.1016/j.siny.2025.101656 · Cited by 5

Chemie und Biologie der Stimulatoren und Aktivatoren der löslichen Guanylatcyclase

Follmann, M., Griebenow, N., Hahn, M. G., Hartung, I. V., Mais, F., Mittendorf, J., Schäfer, M., Schirok, H., Stasch, J., Stoll, F., et al. (2013) · Angewandte Chemie · doi:10.1002/ange.201302588 · Cited by 5

Soluble guanylate cyclase stimulator, trans-4-methoxy-β-nitrostyrene, has a beneficial effect in monocrotaline-induced pulmonary arterial hypertension in rats

Gonzaga‐Costa, K., Vasconcelos‐Silva, A. A., Rodrigues-Silva, M. J., Martins, C. S., Duarte, G. I. B. P., Borges, R. S., Magalhães, P. J. C., & Lahlou, S. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173948 · Cited by 5

Pulmonary Hypertension

Madden, B. P. (2015) · European Cardiology Review · doi:10.15420/ecr.2015.10.01.9 · Cited by 5

Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension associated with congenital heart defects in adults (2021)

Чазова, И. Е., Горбачевский, С. В., Martynyuk, T. V., Shmalts, A. A., Солтановна, В. З., Baryshnikova, I. Y., Glushko, L. A., Владимирович, Г. В., Азизов, В. А., Veselova, T. N., et al. (2022) · Eurasian heart journal · doi:10.38109/2225-1685-2022-1-6-70 · Cited by 5

Pulmonary Arterial Hypertension in Connective Tissue Diseases Beyond Systemic Sclerosis

Lewis, C., Sanderson, R., Vasilottos, N., Zheutlin, A. R., & Visovatti, S. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.08.016 · Cited by 5

Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis

Liu, Y., Qu, Y.-Y., Wang, S., Luo, C., Qiu, H., Li, H., Yuan, P., Wang, L., Li, J., Jiang, R., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1052546 · Cited by 5

Arginine-NO metabolites are associated with morbidity in single ventricle infants undergoing stage 2 palliation

Frank, B. S., Niemiec, S., Khailova, L. S., Mancuso, C. A., Lehmann, T., Mitchell, M. B., Morgan, G. J., Twite, M. D., Maria, M. V. D., Klawitter, J., et al. (2024) · Pediatric Research · doi:10.1038/s41390-024-03162-y · Cited by 5

Clinical trial designs in PAH: shifting from functional measurements to long-term clinical outcomes.

Studer, S. M., & Gilkin, R. J. (2014) · PubMed · Cited by 5

Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases

Adegunsoye, A., Levy, M., & Oyenuga, O. A. (2015) · BioMed Research International · doi:10.1155/2015/929170 · Cited by 5

Therapie des akuten und chronischen Rechtsherzversagens

Kramm, T., Guth, S., Wiedenroth, C. B., Ghofrani, H. A., & Mayer, E. (2016) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-016-0181-9 · Cited by 5

New paradigm for pulmonary arterial hypertension treatment

Tamura, Y., & Channick, R. N. (2016) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000308 · Cited by 5

Genomic Strategies Toward Identification of Novel Therapeutic Targets

Kessler, T., & Schunkert, H. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_360 · Cited by 5

Infections and systemic sclerosis: an emerging challenge

Correa, J. E. B., la Hoz, A. D., López, M. J., Garzón, J., Allanore, Y., & Quintana‐López, G. (2020) · Revista Colombiana de Reumatología (English Edition) · doi:10.1016/j.rcreue.2019.12.004 · Cited by 5

The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat

Gratsianskaya, S. E., Солтановна, В. З., & Martynyuk, T. V. (2020) · Terapevticheskii arkhiv · doi:10.26442/00403660.2020.09.000717 · Cited by 5

Macitentan for the treatment of pulmonary arterial hypertension

Sood, N. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.980403 · Cited by 5

Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison

Wang, C., Jing, Z., Huang, Y., Zhou, D., Liu, Z., Meier, C., Nikkho, S. M., Curram, J., Zhang, P., & He, J. (2016) · Heart Asia · doi:10.1136/heartasia-2015-010712 · Cited by 5

Pulmoner Hipertansiyon ve Weaning

Gunt, C., & Çekmen, N. (2016) · Türk yoğun bakım derneği dergisi/Türk yoğun bakım dergisi · doi:10.4274/tybdd.98698 · Cited by 5

Preoperative balloon pulmonary angioplasty enabled noncardiac surgery of a patient with chronic thromboembolic pulmonary hypertension (CTEPH)

Watanabe, K., Ito, N., Ohata, T., Kariya, T., Inui, H., & Yamada, Y. (2019) · Medicine · doi:10.1097/md.0000000000014807 · Cited by 5

Pulmonary Arterial Hypertension and Therapeutic Interventions

Gabra, N. I., Mahmoud, O., Ishikawa, O., Shah, V., ALTSCHUL, E. L., Oron, M., & Mina, B. A. (2019) · International Journal of Angiology · doi:10.1055/s-0039-1692452 · Cited by 5

Recent advances in the management of pulmonary arterial hypertension: lessons from the upfront combination of ambrisentan and tadalafil

Subías, P. E., Pérez, Á. A., Pérez‐Olivares, C., Climent, L. G., Diago, J. I., & Perelló, M. F. (2021) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2021.1878027 · Cited by 5

Cyclic guanosine monophosphate and 10-year change in left ventricular mass: the Multi-Ethnic Study of Atherosclerosis (MESA)

Subramanya, V., Zhao, D., Ouyang, P., Ying, W., Vaidya, D. M., Ndumele, C. E., Lima, J. A. C., Güallar, E., Hoogeveen, R. C., Shah, S. J., et al. (2021) · Biomarkers · doi:10.1080/1354750x.2021.1893811 · Cited by 5

Riociguat in the Treatment of Pulmonary Arterial Hypertension

Carlos Jerjes-Sánchez, D., Valdez-López, H. G., Zayas, N., Cueto‐Robledo, G., Bonola, L., Pech-Alonso, B., Ramírez, A., Flores-Puente, F., García‐Aguilar, H., Hernández, G. E., et al. (2022) · Archives of Medical Research · doi:10.1016/j.arcmed.2022.04.001 · Cited by 5

New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside… and Back

Parra-Lucares, A., Romero-Hernández, E., Villa, E., Weitz-Muñoz, S., Vizcarra, G., Reyes, M., Vergara, D., Bustamante, S., Llancaqueo, M., V, & Toro, L. (2022) · Biomedicines · doi:10.3390/biomedicines11010070 · Cited by 5

Switching from Beraprost to Selexipag in the Treatment of Pulmonary Arterial Hypertension: Insights from a Phase IV Study of the Japanese Registry (The EXCEL Study: EXChange from bEraprost to seLexipag Study)

Tamura, Y., Kumamaru, H., Tsujino, I., Suda, R., Abe, K., Inami, T., Horimoto, K., Adachi, S., Yasuda, S., Sera, F., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17050555 · Cited by 5

An Elderly Lady with Fever of Unknown Etiology and Severe Pulmonary Hypertension: Intravascular Lymphoma—An Elusive Diagnosis

Sinha, N., Lantigua, L. C., Niazi, M., & Diaz‐Fuentes, G. (2013) · Case Reports in Medicine · doi:10.1155/2013/153798 · Cited by 5

Regulation and Physiological Functions of NO-Sensitive Guanylyl Cyclase

Koesling, D., Russwurm, M., & Mergia, E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804273-1.00008-9 · Cited by 5

Maprotiline Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats

Tong, Y., Jiao, Q., Liu, Y., Lv, J., Wang, R., & Zhu, L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01032 · Cited by 5

The role of pulmonary arterial hypertension-targeted therapy in systemic sclerosis

Lee, M. H., & Bull, T. M. (2019) · F1000Research · doi:10.12688/f1000research.20313.1 · Cited by 5

Pulmonary Assessment of the Liver Transplant Recipient

Panackel, C., Fawaz, M., Jacob, M. O., & Raja, K. (2023) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2023.04.003 · Cited by 4

Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension

Kularatne, M., Boucly, A., Savale, L., Solinas, S., Cheron, C., Roche, A., Jevnikar, M., Jaïs, X., Montani, D., Humbert, M. J. C., et al. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2273395 · Cited by 4

Tai Chi training as a primary care plan for the prevention and management of hypertension: an opinion and positioning article

Zhang, T., Ouyang, C., Liu, W., Bai, Q., & Gao, S. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2320863 · Cited by 4

Antifibrotic therapeutic strategies in systemic sclerosis: Critical role of the Wnt/β-catenin and TGF-β signal transduction pathways as potential targets

Bagheri, L., Javanbakht, M., Malekian, S., Ghahderijani, B. H., Taghipour, S., Tanha, F. D., Ranjkesh, M. H., Cegolon, L., & Zhao, S. G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177607 · Cited by 5

Worldwide Burden of Pulmonary Arterial Hypertension in Adults Aged 65 Years and Older From 1990 to 2021

Zhou, L., Luo, J., Tan, C., Li, Y., Peng, C., & Sun, K. (2025) · Journal of the American Geriatrics Society · doi:10.1111/jgs.70135 · Cited by 4

Resolution of inflammation in pulmonary arterial hypertension, the influence of sex—An IUPHAR immunopharmacology committee review

Landy, C., Blasio, M. J. D., Woodman, O. L., Maffia, P., Peh, H. Y., & Qin, C. X. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70207 · Cited by 4

The NO Pathway as a Target in Patients with Stable and Advanced Heart Failure: An Additional Arrow in Our Quiver!

D’Elia, S., Gentile, C., Solimene, A., Franzese, R., Luisi, E., Caiazzo, A., Marotta, L., Covino, S., Natale, F., Loffredo, F. S., et al. (2025) · Biomolecules · doi:10.3390/biom15101420 · Cited by 5

Pulmonary Hypertension Associated With Left Heart Disease

Khan, M. S., Borlaug, B. A., Butler, J., Gomberg‐Maitland, M., Humbert, M. J. C., Lam, C. S. P., Reddy, Y., Stone, G. W., Zannad, F. M., & Tedford, R. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.01.024 · Cited by 4

A Phase 2, Randomized, Clinical Trial of Inhaled Nitric Oxide for Acute Severe Right Heart Failure With Pulmonary Hypertension (PHiNO Study)

Ogo, T., Ueda, J., Tsuji, A., Asano, R., Hayashi, H., Takano, R., Fujisaki, S., Asakura, K., & Yamamoto, H. (2026) · Circulation Journal · doi:10.1253/circj.cj-26-0119 · Cited by 4

eNOS Uncoupling-ER Stress-Mitochondrial Dysfunction Axis in the Development of Pulmonary Hypertension

Murugesan, P., Zhang, Y., Zhang, M., Zhang, Y., & Cai, H. (2026) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2026.101512 · Cited by 4

Irinotecan and its metabolite SN38 inhibits procollagen I production of dermal fibroblasts from Systemic Sclerosis patients

Lapoirie, J., Tran, L. T.-N., Piazza, L., Contin‐Bordes, C., Truchetet, M., & Bonnet, F. (2021) · Scientific Reports · doi:10.1038/s41598-021-97538-3 · Cited by 4

Impact of Parenteral Prostanoids in Pulmonary Arterial Hypertension: The Relevance of Timing

Papa, S., Scoccia, G., Serino, G., Adamo, F. I., Jabbour, J. P., Caputo, A., Boromei, M., Filomena, D., Laviola, D., Maggio, E., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216840 · Cited by 4

Pharmacological Update and Emerging Treatments of Pulmonary Hypertension

Khan, S. P., Randhawa, S., Patail, H., Spira, Y., Frishman, W. H., Aronow, W. S., & Lanier, G. M. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000647 · Cited by 4

Pulmonary arterial hypertension treatment. A new era

Mouratoglou, S., Arvanitaki, A., Papadopoulos, G., Souza, R., & Giannakoulas, G. A. (2025) · International Journal of Cardiology Congenital Heart Disease · doi:10.1016/j.ijcchd.2025.100594 · Cited by 4

New Pharmacotherapies for Pulmonary Hypertension: Where Do They Fit in?

Wolfson, A., Steiger, N. A., & Gomberg‐Maitland, M. (2014) · Current Hypertension Reports · doi:10.1007/s11906-014-0496-y · Cited by 4

Fibrogenesis, novel lessons from animal models

Langhe, E. D., & Lories, R. J. U. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0510-8 · Cited by 5

Pulmonale Hypertonie

Sommer, N., Hecker, M., Tello, K., Richter, M. J., Liebetrau, C., Weigand, M. A., Seeger, W., Ghofrani, H. A., & Gall, H. J. (2016) · Der Anaesthesist · doi:10.1007/s00101-016-0207-y · Cited by 4

Targeting the NO-sGC-cGMP Pathway in Pulmonary Arterial Hypertension

Watanabe, H., & Tran, Q. (2017) · Springer eBooks · doi:10.1007/978-981-287-840-3_11 · Cited by 4

Treatment of Pediatric Pulmonary Hypertension

Aggarwal, M., & Grady, R. M. (2018) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-018-0597-z · Cited by 4

A disease looking for innovative drugs: The case of pulmonary arterial hypertension

Joppi, R., Gerardi, C., Bertelè, V., & Garattini, S. K. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.05.023 · Cited by 4

Nitrogen oxide biochemical pathway in pulmonary arterial hypertension therapy and REPLACE trial results

Shmalts, A. A., & Gorbachevsky, S. V. (2018) · Systemic Hypertension · doi:10.26442/2075-082x_2018.2.72-76 · Cited by 4

Riociguatas the first innovative guanylatecyclase stimulators class drugs for pulmonary arterial hypertension patients treatment

Chazova, I. E., & Martynyuk, T. V. (2013) · Systemic Hypertension · doi:10.26442/sg28994 · Cited by 4

Balloon pulmonary angioplasty: are we there yet? Lessons learned and unanswered questions

Jevnikar, M., Bokan, A., Gille, T., Bertoletti, L., & Lichtblau, M. (2022) · Breathe · doi:10.1183/20734735.0217-2022 · Cited by 4

The evolving landscape of combination therapy for pulmonary arterial hypertension

Griffin, M. D., & Trow, T. K. (2016) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816677485 · Cited by 4

Intratracheal administration of isosorbide dinitrate improves pulmonary artery pressure and ventricular remodeling in a rat model of heart failure following myocardial infarction

Wang, X., Xu, Q., Li, T., Rong, Y., Hong, W., Huang, Y., & Guo, X. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4707 · Cited by 4

Clinical Characteristics and Factors Associated with Disease Progression in Chinese Patients with Connective Tissue Disease and Pulmonary Arterial Hypertension

Zhang, H., & xiaoyan, X. L. (2020) · Aktuelle Rheumatologie · doi:10.1055/a-1135-8548 · Cited by 4

Assessment of the REPLACE study composite endpoint in riociguat‐treated patients in the PATENT study

Simonneau, G., Ghofrani, H., Corris, P. A., Rosenkranz, S., Grünig, E., White, R. J., McLaughlin, V. V., Langleben, D., Meier, C., Busse, D., et al. (2020) · Pulmonary Circulation · doi:10.1177/2045894020973124 · Cited by 4

Management of Pulmonary Arterial Hypertension Patients with World Health Organization Functional Class II.

Hung, C. C., Cheng, C.-C., Huang, W., Lin, K.-C., Kuo, F. Y., Kuo, S., Yang, T.-H., Liang, H.-L., & Mar, G.-Y. (2020) · PubMed Central · doi:10.6515/acs.202011_36(6).20200507a · Cited by 4

Effects of Dual Initial Combination Therapy With Macitentan Plus Riociguat or Macitentan Plus Selexipag on Hemodynamics in Patients With Pulmonary Arterial Hypertension (SETOUCHI-PH Study) ― Protocol of a Multicenter Randomized Control Trial ―

Akagi, S., Dohi, Y., Ishikawa, K., Kubota, K., Horimoto, K., Yagi, S., Hirata, T., Yamamoto, E., Ito, H., & Nakamura, K. (2021) · Circulation Reports · doi:10.1253/circrep.cr-20-0133 · Cited by 4

Raising the bar to ultradisciplinary collaborations in management of chronic thromboembolic pulmonary hypertension

Akay, H. T., Kaymaz, C., Akar, A. R., Orhan, G., Yanartaş, M., Gültekin, B., Şırlak, M., Kervan, Ü., Taş, S., Biçer, M., et al. (2021) · Turkish Journal of Thoracic and Cardiovascular Surgery · doi:10.5606/tgkdc.dergisi.2021.21284 · Cited by 4

Risk assessment tools for survival prognosis: An era of new surrogacy endpoints for clinical outcome measurement in pulmonary arterial hypertension clinical trials?

Sanna, L., & Todea, A. R. (2022) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2022.100893 · Cited by 4

Pathogenic Mechanisms of Pulmonary Hypertension

Fraidenburg, D. R., & Yuan, J. X. ‐. (2014) · Springer eBooks · doi:10.1007/978-3-642-37078-6_203 · Cited by 4

Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)

Rubin, L. J., Galiè, N., Grimminger, F., Grünig, E., Humbert, M. J. C., Jing, Z., KEOGH, A. M., Langleben, D., Fritsch, A., Menezes, F., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00090614 · Cited by 221

Riociguat for the Treatment of Pulmonary Hypertension: A Meta-analysis of Randomized Controlled Trials

Alrifai, A., Garnet, B., Shah, V., & Lit, L. (2015) · CHEST Journal · doi:10.1378/chest.2281793

Riociguat in Combination With Endothelin Receptor Antagonists (ERAs) for the Treatment of Pulmonary Arterial Hypertension (PAH): A Subgroup Analysis of PATENT

Hill, N. S., & Sood, N. (2015) · CHEST Journal · doi:10.1378/chest.2281116

September 2013 pulmonary journal club: riociguat; pay the doctor

Robbins, R. (2013) · Southwest Journal of Pulmonary and Critical Care · doi:10.13175/swjpcc116-13

Influence of riociguat treatment on pulmonary arterial hypertension

Zhao, R., & Jiang, Y. (2018) · Herz · doi:10.1007/s00059-018-4697-z · Cited by 8